A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/14/2006	CA2610772A1 Composition based on an avermectine and metronidazole in particular for treating rosacea
12/14/2006	CA2610769A1 Composition based on an avermectine and benzoyl peroxide in particular for treating rosacea
12/14/2006	CA2610761A1 Avermectin and hydrocortisone-based composition, in particular for roracea treatment
12/14/2006	CA2610755A1 Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
12/14/2006	CA2610745A1 Therapeutic polymers and methods of use
12/14/2006	CA2610665A1 Hydrates of alkaline-earth salts of irbesartan and the preparation thereof
12/14/2006	CA2610655A1 Cyclobutyl amine derivatives
12/14/2006	CA2610509A1 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
12/14/2006	CA2610465A1 Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
12/14/2006	CA2610448A1 Nanoparticulate imatinib mesylate formulations
12/14/2006	CA2610400A1 Azinone and diazinone v3 inhibitors for depression and stress disorders
12/14/2006	CA2610373A1 Substituted n-benzo [d] isoxazol-3-ylamine derivatives as inhibitors of mglur5, serotonine (5-ht) and noradrenaline receptors, and the use thereof for producing medicaments
12/14/2006	CA2610342A1 Sugar-coated tablet
12/14/2006	CA2610325A1 Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
12/14/2006	CA2610310A1 Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
12/14/2006	CA2610304A1 Peptide deformylase (pdf) inhibitors 4
12/14/2006	CA2610196A1 Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
12/14/2006	CA2610172A1 Heterocyclic compound
12/14/2006	CA2610059A1 1-hydroxycycloalkanecarboxamide derivatives as bradykinin antagonists
12/14/2006	CA2609998A1 Oral ribavirin pharmaceutical compositions
12/14/2006	CA2609969A1 Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
12/14/2006	CA2609815A1 Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
12/14/2006	CA2609583A1 Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
12/14/2006	CA2609560A1 Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
12/14/2006	CA2609343A1 Methods of treating cancer and other conditions or disease states using lfmau and ldt
12/14/2006	CA2608814A1 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
12/14/2006	CA2608631A1 Method and composition for treating inflammatory disorders
12/14/2006	CA2608367A1 Compositions and methods for inhibition of the jak pathway
12/14/2006	CA2607598A1 Treatment with sigma receptor agonists post-stroke
12/14/2006	CA2607337A1 Indole derivatives having antitumor activity
12/14/2006	CA2607184A1 Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents
12/14/2006	CA2606692A1 Inhibitors of soluble adenylate cyclase
12/14/2006	CA2604768A1 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
12/14/2006	CA2601202A1 New hybrid oligomers. their preparation process and pharmaceutical compositions containing them
12/14/2006	CA2600954A1 Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
12/14/2006	CA2574990A1 Antimicrobial copolymers and uses thereof
12/13/2006	EP1731615A1 Cytoplasmic localization dna and rna
12/13/2006	EP1731609A1 Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
12/13/2006	EP1731602A1 Pharmaceutical composition for lowering blood sugar level
12/13/2006	EP1731550A1 Novel water-soluble fullerene, process for producing the same and active oxygen generator containing the fullerene
12/13/2006	EP1731531A2 Multiple cytokine-antibody complexes
12/13/2006	EP1731527A1 Glycoside having 4-methylergost-7-en-3-ol skeleton and drug for ameliorating hyperglycemia
12/13/2006	EP1731524A1 Phenol derivative, medicinal composition containing the same, and medicinal use thereof
12/13/2006	EP1731523A1 Thiazolopyrimidine derivative
12/13/2006	EP1731522A1 Process for producing flavone c glycoside derivatives
12/13/2006	EP1731521A1 Adiponectin increasing agent
12/13/2006	EP1731520A1 Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3
12/13/2006	EP1731519A1 Novel indole derivative for alkylating specific base sequence of dna and alkylating agent and drug each comprising the same
12/13/2006	EP1731516A2 The 9,11-cycloendoperoxide prodrugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
12/13/2006	EP1731513A1 Phenoxyacetic acid derivative and medicine containing the same
12/13/2006	EP1731511A1 BicyclischeI heterocycles, medicaments containing these compounds, their use and methods for the production thereof
12/13/2006	EP1731507A1 New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
12/13/2006	EP1731506A1 5-hydroxyindole-3-carboxylates derivatives and their use
12/13/2006	EP1731505A1 Alkoxyphenylpropanoic acid derivatives
12/13/2006	EP1731502A1 Novel crystal of triterpene derivative
12/13/2006	EP1731193A1 Electro-medical device for use with biologics
12/13/2006	EP1731183A1 Solid pharmaceutical preparation for dialysis
12/13/2006	EP1731175A1 Hemostatic polymer useful for rapid blood coagulation and hemostatis
12/13/2006	EP1731173A1 Complex particles and coated complex particles
12/13/2006	EP1731172A1 Liposome preparation
12/13/2006	EP1731171A1 Preventive/remedy for respiratory diseases
12/13/2006	EP1731170A1 Therapeutic agent for diabetes containing insulin resistance improving agent
12/13/2006	EP1731169A1 Remedies for prostatic hypertrophy
12/13/2006	EP1731162A2 Apparatus, method and compositions for the treatment of cancers by ultraphoresis
12/13/2006	EP1731161A1 Compositions for the treatment of diseases associated with elevated sphingolipid concentrations
12/13/2006	EP1731158A1 Drugs, foods and drinks for ameliorating hyperglycemia
12/13/2006	EP1731157A2 Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
12/13/2006	EP1731156A1 Pharmaceutical compositions to treat or prevent cerebral oedema
12/13/2006	EP1731155A2 Beta-D-2', 3' -Didehydro-2',3' -Dideoxy-5-Fluorocydine for use in the treatment of HIV infections
12/13/2006	EP1731154A1 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)\|4-(4-pyridylmethyl)pht halazin-1-yl\| and salts thereof
12/13/2006	EP1731153A1 Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl\| and salts thereof
12/13/2006	EP1731152A2 Sustained analgesia achieved with transdermal delivery of buprenorphine
12/13/2006	EP1731151A1 Solid pharmaceutical preparation containing sparingly water-soluble drug
12/13/2006	EP1731150A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof
12/13/2006	EP1731149A1 Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
12/13/2006	EP1731148A1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer
12/13/2006	EP1731147A1 External preparation
12/13/2006	EP1731146A1 Prevention and measure for mitochondrial disease
12/13/2006	EP1731145A1 Use of glycerol for improving cardiac function
12/13/2006	EP1731144A1 Identification of genes altered in multiple myeloma
12/13/2006	EP1731143A1 Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
12/13/2006	EP1731141A2 Gastric acid secretion inhbiting compositon
12/13/2006	EP1731140A2 Medicinal aerosol formulation
12/13/2006	EP1731139A1 S/o type pharmaceutical preparation and process for producing the same
12/13/2006	EP1731138A1 Fine dispersion of sparingly soluble drug and process for producing the same
12/13/2006	EP1731135A1 Cosmetic, pharmaceutical and dermatological compositions containing homo- and/or copolymer waxes of the monomers ethylene and/or propylene
12/13/2006	EP1731134A1 Functional powders
12/13/2006	EP1731131A1 Hgf production accelerator containing heparin-like oligosaccharide
12/13/2006	EP1731042A1 Feed additive for laying hens and feed containing the additive
12/13/2006	EP1731036A1 Synergistic mixtures containing 1,2-alkanediols
12/13/2006	EP1730600A1 Composition and process for post-etch removal of photoresist and/or sacrificial anti-reflective material deposited on a substrate
12/13/2006	EP1730522A2 Methods for treating dermatological conditions in a patient
12/13/2006	EP1730310A2 A formulation for increasing endogenous adiponectin and leptin production
12/13/2006	EP1730306A2 Polymorphisms in the epidermal growth factor receptor gene promoter
12/13/2006	EP1730286A2 Therapeutic anti-cancer dna
12/13/2006	EP1730279A2 Epha4 as therapeutic target of prc and pdaca
12/13/2006	EP1730190A2 Inhibiting cav3 isoforms and the &25b splice varients for the diagnosis and treatment of cancer
12/13/2006	EP1730185A1 Cancer associated antigens
12/13/2006	EP1730166A2 Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
12/13/2006	EP1730165A1 Inhibitors of hepatitis c virus ns3 protease

1 ... 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 3980 3981 3982 3983 3984 3985 3986 3987 3988 ... 7860